Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Plans To Shed 13% Of Work Force By 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.

You may also be interested in...



Meet Merck’s Dealmaker: A Conversation With Roger Pomerantz

Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.

Vertex Takes Early Lead In HCV Protease Inhibitor Sales

Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.

Despite Recent Setbacks, Merck's CV Pipeline Is Strong

The Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.

Related Content

Topics

UsernamePublicRestriction

Register

PS072587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel